The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017.

Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)

Studie: PAZOREAL; Indikation: Nierenzellkarzinom; Jahr: 2017; Veranstaltung: -; Journal: Future Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com